IL6 and injury: Other examples include Campath H-1 targeting CD52 on lymphocytes and monocytes with resulting elevated levels of TNF-α, IFN- ү, and IL-6; rituximab (anti-CD20) resulting in rapid increases in TNF-α and IL-6; and visilizumab (anti-CD3) induced cytokine release syndrome resulting in liver injury [6].